Pharmaceutical

Opinion: Lessons from Ukraine on protecting mental heal...

Sane Ukraine’s work offers an important new path for improving mental health in ...

STAT+: FDA panel votes against GLP-1 therapy from forme...

An FDA advisory panel unanimously voted against a diabetes implant from Intarcia...

AlphaFold developers and eye scan inventors among Laske...

Demis Hassabis and John Jumper received the Albert Lasker Basic Medical Research...

STAT+: Four burning questions about the potential 85,00...

More than 75,000 Kaiser Permanente health care workers have voted to authorize a...

Senate HELP on collision course

D.C. Diagnosis is STAT's twice-weekly newsletter about health care politics and ...

A thorny ALS debate at the FDA, and the promise of arti...

Can the FDA be too flexible? How do you test a mechanical womb? And who decides ...

STAT+: Thermo Fisher just opened a $180 million plant. ...

The two-story building — and the $180 million Thermo Fisher spent to build it — ...

STAT+: Bernie Sanders, Bill Cassidy clash over proposal...

In a striking display of discord, leaders of the Senate’s health committee clash...

FTC sues private equity firm Welsh Carson, U.S. Anesthe...

The Federal Trade Commission alleged Welsh Carson and U.S. Anesthesia Partners f...

STAT+: What the Dana-Farber, Brigham divorce means for ...

“This is going to be really tricky for five years between now and the end of our...

STAT+: Travere kidney drug narrowly fails confirmatory ...

Travere called the results “clinically meaningful” and said they would bring the...

AbCellera and Regeneron expand antibody discovery colla...

AbCellera and Regeneron have extended their current multi-target collaboration t...

EC grants approval for Menarini’s breast cancer therapy

The European Commission granted approval for The Menarini Group’s Orserdu to tre...

Launching pharmaceuticals in Belgium, the Netherlands, ...

Benelux offers much potential for companies distributing innovative medicines, b...

Signal: Fresh Tracks nears end of operations with plans...

Fresh Tracks is planning to seek approval for liquidation and dissolution from s...

FDA accepts Takeda’s NDA resubmission for eosinophilic ...

The US FDA has accepted Takeda’s NDA resubmission for TAK-721 for the short-term...